Financial Snapshot

Revenue
$1.252M
TTM
Gross Margin
79.01%
TTM
Net Earnings
-$358.8K
TTM
Current Assets
$290.9K
Q2 2024
Current Liabilities
$1.271M
Q2 2024
Current Ratio
22.88%
Q2 2024
Total Assets
$1.362M
Q2 2024
Total Liabilities
$1.345M
Q2 2024
Book Value
$16.17K
Q2 2024
Cash
P/E
-183.1
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $628.6K $679.8K $702.8K
YoY Change -7.53% -3.27%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $628.6K $679.8K $702.8K
Cost Of Revenue $157.8K $121.6K $112.0K
Gross Profit $470.8K $558.2K $590.8K
Gross Profit Margin 74.9% 82.11% 84.06%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $693.0K $456.9K $371.4K
YoY Change 51.68% 23.01%
% of Gross Profit 147.19% 81.86% 62.88%
Research & Development $84.47K $73.72K $81.22K
YoY Change 14.58% -9.23%
% of Gross Profit 17.94% 13.21% 13.75%
Depreciation & Amortization $63.13K $54.08K $65.95K
YoY Change 16.73% -18.0%
% of Gross Profit 13.41% 9.69% 11.16%
Operating Expenses $777.5K $530.6K $452.7K
YoY Change 46.53% 17.22%
Operating Profit -$306.7K $27.52K $138.1K
YoY Change -1214.39% -80.07%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $46.17K $43.51K $65.44K
YoY Change 6.11% -33.51%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$260.5K $71.03K $203.5K
YoY Change -466.76% -65.1%
Income Tax -$19.29K -$12.95K $11.07K
% Of Pretax Income -18.23% 5.44%
Net Earnings -$241.2K $83.98K $192.5K
YoY Change -387.24% -56.36%
Net Earnings / Revenue -38.37% 12.35% 27.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.02 $0.01 $0.02

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $217.9K $72.29K $136.8K
YoY Change 201.41% -47.14%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $27.87K $18.65K $13.01K
YoY Change 49.44% 43.35%
Inventory $52.26K $152.8K $99.43K
Prepaid Expenses
Receivables $206.3K $448.1K $209.5K
Other Receivables $28.13K $27.02K $557.3K
Total Short-Term Assets $532.5K $718.8K $1.016M
YoY Change -25.92% -29.25%
Property, Plant & Equipment $215.0K $217.9K $295.7K
YoY Change -1.34% -26.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $869.2K $465.0K $19.25K
YoY Change 86.91% 2315.58%
Total Long-Term Assets $1.084M $682.9K $315.0K
YoY Change 58.76% 116.83%
Total Assets $1.617M $1.402M $1.331M
YoY Change
Accounts Payable $18.00K $11.17K $24.43K
YoY Change 61.15% -54.28%
Accrued Expenses $88.64K $86.31K $85.94K
YoY Change 2.7% 0.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.205M $680.4K $135.8K
YoY Change 77.16% 401.14%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $105.0K $165.0K $240.9K
YoY Change -36.37% -31.5%
Total Long-Term Liabilities $105.0K $165.0K $240.9K
YoY Change -36.37% -31.5%
Total Liabilities $1.310M $845.4K $376.7K
YoY Change 55.0% 124.46%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $65.692 Million

About Pheton Holdings Ltd

Pheton Holdings Ltd is a CN-based company operating in Health Care Technology industry. The company is headquartered in Beijing, Beijing and currently employs 11 full-time employees. The company went IPO on 2024-09-05. Pheton Holdings Ltd is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: